Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elisabetta Zanatta

Showing results (61-70 of 98) with videos related to

Pageof 10
Sort By:
Chest|June 7, 2024
Diffusing Capacity of the Lungs for Carbon Monoxide and Echocardiographic Parameters in Identifying Mild Pulmonary Hypertension in the EUSTAR Cohort of Patients With Systemic SclerosisAmalia Colalillo, Eric Hachulla, Chiara Pellicano, et al.
Rheumatology (Oxford, England)|March 29, 2022
Phenotype of limited cutaneous systemic sclerosis patients with positive anti-topoisomerase I antibodies: data from the EUSTAR cohortElisabetta Zanatta, Dörte Huscher, Augusta Ortolan, et al.
Rheumatology (Oxford, England)|September 13, 2022
Glucocorticoids prescribing practices in systemic sclerosis: an analysis of the EUSTAR databaseMichele Iudici, Denis Mongin, Elise Siegert, et al.
Rheumatology (Oxford, England)|June 22, 2022
Late skin fibrosis in systemic sclerosis: a study from the EUSTAR cohortMichael Hughes, Suiyuan Huang, Juan Jose Alegre-Sancho, et al.
RMD Open|May 21, 2024
Untangling the relationship between smoking and systemic sclerosis: an analysis of the EUSTAR cohortJacopo Ciaffi, Sophie I E Liem, Suzanne Cannegieter, et al.
Arthritis Research & Therapy|November 1, 2024
Does regression of skin thickening predict improvement of internal organ involvement and survival in patients with diffuse cutaneous systemic sclerosis? A EUSTAR analysisAnja Wyss, Suzana Jordan, Nicole Graf, et al.
RMD Open|February 22, 2023
Real-life efficacy and safety of nintedanib in systemic sclerosis-interstitial lung disease: data from an Italian multicentre studyCorrado Campochiaro, Giacomo De Luca, Maria-Grazia Lazzaroni, et al.
RMD Open|August 4, 2023
Interstitial lung disease with and without progressive fibrosing phenotype in patients with idiopathic inflammatory myopathies: data from a large multicentric cohortElisabetta Zanatta, Elisabetta Cocconcelli, Gioele Castelli, et al.
Rheumatology (Oxford, England)|May 15, 2024
Rituximab retention rate in systemic sclerosis: a long term real-life multicentre studyGiacomo De Luca, Enrico De Lorenzis, Corrado Campochiaro, et al.
Annals of the Rheumatic Diseases|August 19, 2019
Revised European Scleroderma Trials and Research Group Activity Index is the best predictor of short-term severity accrualSerena Fasano, Antonella Riccardi, Valentina Messiniti, et al.
Pageof 10

Showing results (61-70 of 98) with videos related to

Sort By:
Pageof 10
Chest|June 7, 2024
Diffusing Capacity of the Lungs for Carbon Monoxide and Echocardiographic Parameters in Identifying Mild Pulmonary Hypertension in the EUSTAR Cohort of Patients With Systemic SclerosisAmalia Colalillo, Eric Hachulla, Chiara Pellicano, et al.
Rheumatology (Oxford, England)|March 29, 2022
Phenotype of limited cutaneous systemic sclerosis patients with positive anti-topoisomerase I antibodies: data from the EUSTAR cohortElisabetta Zanatta, Dörte Huscher, Augusta Ortolan, et al.
Rheumatology (Oxford, England)|September 13, 2022
Glucocorticoids prescribing practices in systemic sclerosis: an analysis of the EUSTAR databaseMichele Iudici, Denis Mongin, Elise Siegert, et al.
Rheumatology (Oxford, England)|June 22, 2022
Late skin fibrosis in systemic sclerosis: a study from the EUSTAR cohortMichael Hughes, Suiyuan Huang, Juan Jose Alegre-Sancho, et al.
RMD Open|May 21, 2024
Untangling the relationship between smoking and systemic sclerosis: an analysis of the EUSTAR cohortJacopo Ciaffi, Sophie I E Liem, Suzanne Cannegieter, et al.
Arthritis Research & Therapy|November 1, 2024
Does regression of skin thickening predict improvement of internal organ involvement and survival in patients with diffuse cutaneous systemic sclerosis? A EUSTAR analysisAnja Wyss, Suzana Jordan, Nicole Graf, et al.
RMD Open|February 22, 2023
Real-life efficacy and safety of nintedanib in systemic sclerosis-interstitial lung disease: data from an Italian multicentre studyCorrado Campochiaro, Giacomo De Luca, Maria-Grazia Lazzaroni, et al.
RMD Open|August 4, 2023
Interstitial lung disease with and without progressive fibrosing phenotype in patients with idiopathic inflammatory myopathies: data from a large multicentric cohortElisabetta Zanatta, Elisabetta Cocconcelli, Gioele Castelli, et al.
Rheumatology (Oxford, England)|May 15, 2024
Rituximab retention rate in systemic sclerosis: a long term real-life multicentre studyGiacomo De Luca, Enrico De Lorenzis, Corrado Campochiaro, et al.
Annals of the Rheumatic Diseases|August 19, 2019
Revised European Scleroderma Trials and Research Group Activity Index is the best predictor of short-term severity accrualSerena Fasano, Antonella Riccardi, Valentina Messiniti, et al.
Pageof 10